Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient’s response to androg...

Descripció completa

Dades bibliogràfiques

Autors principals:	Gaetano Aurilio, Alessia Cimadamore, Roberta Mazzucchelli, Antonio Lopez-Beltran, Elena Verri, Marina Scarpelli, Francesco Massari, Liang Cheng, Matteo Santoni, Rodolfo Montironi
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2020-12-01
Col·lecció:	Cells
Matèries:	prostate cancer androgen receptor AR-V7 AR variants AR antagonists AR resistance
Accés en línia:	https://www.mdpi.com/2073-4409/9/12/2653
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!